ALXO ALX ONCOLOGY HOLDINGS INC
Pharmaceutical Preparations · Nasdaq · SEC CIK 1810182 · Fiscal year ends 12/31
Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY—
TTM net income YoY25.4%
TTM EPS YoY56.7%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—
Returns
ROE-94.4%
ROA-67.9%
ROIC (approx.)-99.6%
Asset turnover—
Leverage & solvency
Liabilities / assets18.6%
Debt / equity0.08x
Current ratio8.04x
Interest coverage-67.78x
Cash quality & payout
Operating cash flow / net income0.85x
Accruals ratio-10.2%
Payout ratio—
Capex / revenue—
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | FY20252025-12-31 | FY20242024-12-31 |
|---|---|---|
| Income statement | ||
| Revenue | — | — |
| R&D expense | $77.00M | $116.37M |
| SG&A expense | $23.85M | $26.09M |
| Operating income | -$104.02M | -$142.47M |
| Interest expense | $1.60M | $1.73M |
| Pretax income | -$101.69M | -$134.85M |
| Income tax | $0 | $0 |
| Net income | -$101.69M | -$134.85M |
| EBITDA | -$103.31M | -$141.59M |
| EPS (basic) | -1.90 | -2.58 |
| EPS (diluted) | -1.90 | -2.58 |
| Weighted avg. shares (diluted) | 53.66M | 52.17M |
| Balance sheet | ||
| Cash & equivalents | $16.37M | $17.63M |
| Short-term investments | $28.42M | $110.19M |
| Current assets | $50.73M | $134.35M |
| PP&E, net | $1.20M | $2.90M |
| Total assets | $59.05M | $147.78M |
| Current liabilities | $24.55M | $18.50M |
| Short-term debt | $5.22M | $435,000 |
| Long-term debt | $4.53M | $9.47M |
| Total debt | $9.75M | $9.90M |
| Total liabilities | $33.06M | $34.16M |
| Shareholders' equity | $25.98M | $113.62M |
| Net debt | -$6.62M | -$7.73M |
| Shares outstanding | 54.39M | 53.05M |
| Cash flow statement | ||
| Operating cash flow | -$84.14M | -$121.91M |
| Capital expenditure | $212,000 | $447,000 |
| Free cash flow | -$84.35M | -$122.36M |
| Investing cash flow | $82.59M | $86.26M |
| Financing cash flow | $362,000 | $30.82M |
| Depreciation & amortization | $706,000 | $872,000 |
| Stock-based compensation | $12.58M | $27.09M |
Free plan shows the latest 2 periods; Pro shows all 8 🔒
· This company does not report gross profit in XBRL.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.